Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

Running, not enrolling · Phase 3

Conditions studied: Pneumococcal Immunization

In brief

This study is a Phase 3, randomized, modified double-blind study which aims to measure whether the investigational pneumococcal conjugate vaccine PCV21 is safe and can help the body to develop germ-fighting agents called "antibodies" (immunogenicity) when it is given after 1 dose, 2 doses, or 3 doses of a licensed 20-valent pneumococcal vaccine compared to when 20-valent pneumococcal vaccine is given as a complete series in infants aged from approximately 2 months (42 to 89 days). The study duration per participant will be up to approximately 19 months. The study vaccines (either PCV21 or 20vPCV) will be administered at approximately 2, 4, 6 and 12 to 15 months of age (MoA). Routine pediatric vaccines will be given as per local recommendations. There will be 6 study visits: Visit (V)01, V02 separated from V01 by 60 days, V03 separated from V02 by 60 days, V04 separated from V03 by 30 days, V05 at 12 months of age until 15 months of age, V06 separated from V05 by 30 days.

Key facts

Study ID

NCT06824181

Run by

Sanofi

People needed

580

Starts

2025-02-27

Expected to finish

2027-09-10

Last updated by the study team

2026-02-13

Who can join

Age: 0 and older, up to 0. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Aged 42 to 89 days on the day of inclusion
• Participants who are healthy as determined by medical evaluation including medical history and physical examination
• Born at full term of pregnancy (≥ 37 weeks) and with a birth weight ≥ 2.5 kg or born after a gestation period above 28 (> 28 weeks) through 36 weeks with a birth weight ≥ 1.5 kg, and in both cases medically stable as assessed by the investigator

You may not qualify if…

• Participants are excluded from the study if any of the following criteria apply:
• Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy; or long-term systemic corticosteroid therapy
• History of microbiologically confirmed Streptococcus pneumoniae infection or disease.
• History of seizure or significant stable or progressive neurologic disorders such as inflammatory nervous system diseases, encephalopathy, cerebral palsy
• Known systemic hypersensitivity to any of the study interventions components, or history of a life-threatening reaction to the study interventions used in the study or to a product containing any of the same substances
• Thrombocytopenia, or known thrombocytopenia, as reported by the parent/legal acceptable representative (LAR), contraindicating intramuscular (IM) injection.
• Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating IM injection
• Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion
• Moderate or severe acute illness/infection (according to investigator judgment) or febrile illness (temperature ≥ 38.0°C [≥ 100.4°F]) on the day of study intervention administration. A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided.
• Previous vaccination against Streptococcus pneumoniae
• Receipt of immune globulins, blood or blood-derived products since birth
• Participation at the time of study enrollment (or in the 6 weeks preceding the first study intervention administration) or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure
• Note: The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

Where it is running

• Kaiser Permanente - Los Angeles Medical Center- Site Number : 8400025 — Los Angeles, California, United States
• The Medici Medical Research- Site Number : 8400008 — Hollywood, Florida, United States
• Clinsearch Inc at Dr. Gala, LLC- Site Number : 8400027 — Miami, Florida, United States
• Atlantis Clinical Research- Site Number : 8400009 — Miami, Florida, United States
• Velocity Clinical Research - Sioux City- Site Number : 8400007 — Sioux City, Iowa, United States
• Private Practice - Dr. Michael W. Simon- Site Number : 8400001 — Lexington, Kentucky, United States
• Velocity Clinical Research - New Orleans- Site Number : 8400006 — New Orleans, Louisiana, United States
• Finger Lakes Medical Research - Cortland- Site Number : 8400022 — Cortland, New York, United States
• University of Rochester Medical Center- Site Number : 8400019 — Rochester, New York, United States
• SUNY Upstate Medical University - Syracuse- Site Number : 8400015 — Syracuse, New York, United States
• Kid's Way Pediatrics- Site Number : 8400013 — Hermitage, Pennsylvania, United States
• Carolina Family Care - Charleston- Site Number : 8400014 — Charleston, South Carolina, United States
• Helios Clinical Research - BUR PEDI- Site Number : 8400016 — Burleson, Texas, United States
• Clinsearch Inc at VAST Clinical Research- Site Number : 8400028 — Euless, Texas, United States
• DM Clinical Research - Houston - Jones Road- Site Number : 8400012 — Houston, Texas, United States
• University of Texas Medical Branch at Galveston- Site Number : 8400005 — League City, Texas, United States
• Javara - Privia Medical Group North Texas - Stephenville- Site Number : 8400024 — Stephenville, Texas, United States
• Investigational Site Number : 1520003 — Santiago, Reg Metropolitana de Santiago, Chile
• Investigational Site Number : 1520002 — Santiago, Reg Metropolitana de Santiago, Chile
• Investigational Site Number : 1520001 — Santiago, Reg Metropolitana de Santiago, Chile
• Investigational Site Number : 4840003 — León, Guanajuato, Mexico
• Investigational Site Number : 4840001 — Mexico City, Mexico City, Mexico
• Investigational Site Number : 4840002 — Temixco, Morelos, Mexico
• Investigational Site Number : 4840004 — Tlaltizapán, Morelos, Mexico
• Investigational Site Number : 6080001 — Cebu City, Philippines

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.